In a filing, Zevra Therapeutics Inc revealed its Director FAVORITO TAMARA A acquired Company’s shares for reported $24718.0 on Sep 12 ’25. In the deal valued at $7.79 per share,3,175 shares were bought. As a result of this transaction, FAVORITO TAMARA A now holds 3,894 shares worth roughly $31580.339999999997.
Then, Shih Alvin bought 20,000 shares, generating $157,800 in total proceeds. Upon buying the shares at $7.89, the Director now owns 20,000 shares.
Before that, Bode John B bought 5,000 shares. Zevra Therapeutics Inc shares valued at $45,825 were divested by the Director at a price of $9.16 per share. As a result of the transaction, Bode John B now holds 45,000 shares, worth roughly $0.36 million.
H.C. Wainwright initiated its Zevra Therapeutics Inc [ZVRA] rating to a Buy in a research note published on July 02, 2025; the price target was $26. Guggenheim began covering ZVRA with “Buy” recommendation on October 07, 2024. Maxim Group maintained its rating on September 24, 2024. It rated ZVRA as “a Buy”.
Price Performance Review of ZVRA
On Tuesday, Zevra Therapeutics Inc [NASDAQ:ZVRA] saw its stock jump 2.01% to $8.11. Over the last five days, the stock has gained 11.71%. Zevra Therapeutics Inc shares have risen nearly 1.12% since the year began. Nevertheless, the stocks have fallen -2.76% over the past one year. While a 52-week high of $13.16 was reached on 07/15/25, a 52-week low of $6.19 was recorded on 04/09/25.
Levels Of Support And Resistance For ZVRA Stock
The 24-hour chart illustrates a support level at 7.91, which if violated will result in even more drops to 7.72. On the upside, there is a resistance level at 8.27. A further resistance level may holdings at 8.43.
How much short interest is there in Zevra Therapeutics Inc?
A steep rise in short interest was recorded in Zevra Therapeutics Inc stocks on 2025-08-29, growing by 2.25 million shares to a total of 6.89 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 4.64 million shares. There was a rise of 32.68%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 24, 2024 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $17 price target.
